Compare TPC & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | AMRX |
|---|---|---|
| Founded | 1894 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 2003 | 2018 |
| Metric | TPC | AMRX |
|---|---|---|
| Price | $78.68 | $18.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $86.00 | $15.60 |
| AVG Volume (30 Days) | 528.0K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | 148.24 | ★ 157.89 |
| EPS | ★ 0.48 | 0.19 |
| Revenue | ★ $5,543,039,000.00 | N/A |
| Revenue This Year | $15.37 | $4.48 |
| Revenue Next Year | $9.99 | $7.13 |
| P/E Ratio | $164.55 | ★ $90.68 |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $43.52 | $7.67 |
| 52 Week High | $100.00 | $17.86 |
| Indicator | TPC | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 73.45 |
| Support Level | $75.61 | $12.46 |
| Resistance Level | $89.46 | N/A |
| Average True Range (ATR) | 3.16 | 0.56 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 48.97 | 98.16 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.